Summary:
In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg subcutaneous injection weekly significantly reduced NT-proBNP by 18% (treatment ratio 0.82, P=0.0002) and improved health status, with greater KCCQ benefits (up to 11.9 points) in higher baseline NT-proBNP tertiles compared to matching placebo, with consistent weight loss across NT-proBNP tertiles and no significant safety concerns.
| PICO | Description |
|---|---|
| Population | 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30) from STEP-HFpEF trials. |
| Intervention | Semaglutide 2.4 mg subcutaneous weekly, titrated over 16 weeks. |
| Comparison | Matching placebo injection weekly. |
| Outcome | NT-proBNP reduced 18%. KCCQ improved up to 11.9 points in highest tertile. Weight loss consistent. No safety concerns. |
STEP-HFpEF: Semaglutide & NT-proBNP
Pooled RCT analysis · obesity HFpEF · 52 wk
Semaglutide 2.4 mg cut NT-proBNP by 18% (ratio 0.82) versus placebo in obesity-related HFpEF, with the largest health-status gains in patients with the highest baseline NT-proBNP.
Clinical Context
Obesity-related HFpEF is characterized by volume overload, metabolic dysfunction, and impaired quality of life. NT-proBNP reflects cardiac wall stress.
Clinical Pearls
1. Biomarker Reduction Beyond Weight Loss: The 18% NT-proBNP reduction suggests cardiac unloading beyond weight loss alone.
2. Greater Benefit with Higher Baseline NT-proBNP: Patients with highest cardiac stress showed the largest QoL improvements (11.9 KCCQ points).
3. Consistent Weight Loss Across Subgroups: Weight loss similar regardless of baseline NT-proBNP.
4. KCCQ as Clinically Meaningful Endpoint: 10+ points represent substantial symptomatic benefit.
Practical Application
Consider semaglutide for obesity-related HFpEF, especially with elevated NT-proBNP. Integrate with SGLT2 inhibitors and standard HFpEF management.
Study Limitations
Pooled analysis. NT-proBNP is a surrogate marker. 52-week duration. Patients with very advanced HF may have been underrepresented.
Bottom Line
Semaglutide reduces NT-proBNP by 18% and substantially improves quality of life in obesity-related HFpEF, with greatest benefits in those with highest baseline NT-proBNP.
Source: Petrie MC, et al. “Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.” J Am Coll Cardiol. 2024. Read article